MX2022011725A - Metodos para tratar una lesion pulmonar con inhibidores de cgrp. - Google Patents

Metodos para tratar una lesion pulmonar con inhibidores de cgrp.

Info

Publication number
MX2022011725A
MX2022011725A MX2022011725A MX2022011725A MX2022011725A MX 2022011725 A MX2022011725 A MX 2022011725A MX 2022011725 A MX2022011725 A MX 2022011725A MX 2022011725 A MX2022011725 A MX 2022011725A MX 2022011725 A MX2022011725 A MX 2022011725A
Authority
MX
Mexico
Prior art keywords
methods
treating pulmonary
pulmonary injury
cgrp
cgrp inhibitors
Prior art date
Application number
MX2022011725A
Other languages
English (en)
Inventor
Vladimir Coric
Charles M Conway
St John Donnie Mcgrath
Reese M Caldwell
Steven M Schnittman
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of MX2022011725A publication Critical patent/MX2022011725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporciona un método para tratar la COVID-19 en un paciente que lo necesita, en donde el método incluye administrar al paciente una cantidad terapéuticamente eficaz de un inhibidor de CGRP. También se proporciona una composición farmacéutica para tratar la COVID-19 en un paciente que lo necesita, en donde la composición farmacéutica incluye una cantidad terapéuticamente eficaz de un inhibidor de CGRP.
MX2022011725A 2020-03-23 2021-03-22 Metodos para tratar una lesion pulmonar con inhibidores de cgrp. MX2022011725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062993451P 2020-03-23 2020-03-23
PCT/US2021/023388 WO2021194918A1 (en) 2020-03-23 2021-03-22 Methods of treating pulmonary injury with cgrp inhibitors

Publications (1)

Publication Number Publication Date
MX2022011725A true MX2022011725A (es) 2022-10-10

Family

ID=77892226

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011725A MX2022011725A (es) 2020-03-23 2021-03-22 Metodos para tratar una lesion pulmonar con inhibidores de cgrp.

Country Status (11)

Country Link
US (1) US20230285390A1 (es)
EP (1) EP4126002A4 (es)
JP (1) JP2023532617A (es)
KR (1) KR20220158245A (es)
CN (1) CN115697378A (es)
AU (1) AU2021244192A1 (es)
BR (1) BR112022018948A2 (es)
CA (1) CA3176072A1 (es)
IL (1) IL296688A (es)
MX (1) MX2022011725A (es)
WO (1) WO2021194918A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151214A1 (en) * 2021-09-20 2023-03-22 Universidade Nova De Lisboa Rimegepant for treatment of human coronavirus infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2242768A4 (en) * 2008-01-17 2012-03-14 Humabs Llc CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION
JP2017515852A (ja) * 2014-05-16 2017-06-15 ソーク インスティテュート フォー バイオロジカル スタディーズ 代謝障害を処置するための組成物および方法
GB201519196D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
US11400136B2 (en) * 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
SG11202009199YA (en) * 2018-03-25 2020-10-29 Biohaven Pharm Holding Co Ltd Rimegepant for cgrp related disorders

Also Published As

Publication number Publication date
WO2021194918A1 (en) 2021-09-30
US20230285390A1 (en) 2023-09-14
CN115697378A (zh) 2023-02-03
KR20220158245A (ko) 2022-11-30
EP4126002A4 (en) 2024-04-10
JP2023532617A (ja) 2023-07-31
EP4126002A1 (en) 2023-02-08
BR112022018948A2 (pt) 2022-11-16
AU2021244192A1 (en) 2022-11-17
IL296688A (en) 2022-11-01
CA3176072A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
EA202190630A1 (ru) Способы комбинированной терапии
MX2021008751A (es) Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2022015900A (es) Inhibidores de alk2 para el tratamiento de la anemia.
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2022004806A (es) Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763).
EA202000298A1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022016367A (es) Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
EA202193276A1 (ru) Способы лечения холангиокарциномы
AR117292A1 (es) Terapias combinadas para tratar enfermedades usando un modificador inmunológico innato y un agonista de ox40
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
MX2022009914A (es) El acido margarico disminuye el dolor mediado por piez02.
ZA202202673B (en) Methods and compositions for treating endometriosis
TW202419088A (zh) 使用ｊａｋ抑制劑之蕁麻疹治療
ZA202212095B (en) Il4i1 inhibitors and methods of use